Confronto
FOXO4-DRI vs. Teduglutid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
2074706-72-8
197922-42-2
Peso molecolare
3735 g/mol
3752.13 g/mol
Emivita
0.5 h
nessun dato
Sequenza
D-Retro-Inverso-Variante eines FOXO4-Peptid-Fragments (LTLRKEPASEIAQSILEAYSQNGWANRRSGGKR — D-Aminosäuren in umgekehrter Sequenz)nessun dato
Meccanismo d'azione
FOXO4-DRI
FOXO4-DRI is the D-retro-inverso variant of a peptide fragment of the FOXO4 transcription factor. In senescent cells, FOXO4 is bound to p53, which suppresses p53-mediated apoptosis — the cells survive in a secreting 'zombie-like' state (senescence-associated secretory phenotype, SASP). The DRI peptide disrupts this FOXO4-p53 binding, freeing p53, and the senescent cell initiates apoptosis. Healthy cells are largely unaffected because p53 is not held back by FOXO4 in them. This selectivity was the central finding of the original 2017 publication.
Teduglutid
Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.
Base di evidenze
Evidenza più alta
Modello animale
RCT sull'uomo
Studi
3
2
di cui sull'uomo
0
2
Effetti registrati
3
2
Contraddizioni aperte
1
0
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between FOXO4-DRI and Teduglutid?
- FOXO4-DRI is classified as "Ricerca (altro)", while Teduglutid is classified as "Ricerca (altro)". FOXO4-DRI: Synthetic peptide with D-Retro-Inverso structure (all amino acids as D-form, sequence reversed), developed in 2017 as an experimental senolytic candidate. Goal: selective apoptosis of senescent cells via disruption of the FOXO4-p53 interaction. So far evaluated exclusively preclinically. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, FOXO4-DRI or Teduglutid?
- The highest available evidence level is "Modello animale" for FOXO4-DRI and "RCT sull'uomo" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of FOXO4-DRI and Teduglutid in Germany and the United States?
- Germania: FOXO4-DRI — Solo ricerca, Teduglutid — Su prescrizione. Stati Uniti: FOXO4-DRI — Solo ricerca, Teduglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.